Salicornia extract improves memory in mild cognitive impairment
Original article reference
- Original title: Effect of desalted Salicornia europaea L. ethanol extract (PM EE) on the subjects complaining memory dysfunction without dementia: a 12 week, randomized, double blind, placebo controlled clinical trial
- Published in: Scientific Reports (Nature), 2020, Vol. 10, Artículo 19914
- DOI: 10.1038/s41598-020-76938-x
Abstract paper
This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and efficacy of a desalted Salicornia europaea ethanol extract (PM-EE) for 12 weeks in 63 individuals complaining of memory impairment but without a diagnosis of dementia.
Although no significant differences were observed in the primary ADAS-cog test results in the overall group, notable improvements in executive functions and language comprehension were detected in a subgroup of patients with mild cognitive impairment (MCI). Furthermore, the treatment was safe and well tolerated, with no significant adverse effects.
Key points
- Double-blind human clinical trial, 63 participants with memory complaints without dementia.
- Treatment: 600 mg/day of dehydrated Salicornia europaea extract (PM-EE) for 12 weeks.
- Demonstrated safety: no serious side effects, well tolerated.
- In the subgroup with mild cognitive impairment (MCI):
- Significant improvement in the Stroop Test (frontal executive function).
- Improvement in spoken language comprehension.
- Previous animal studies have shown that this extract inhibits acetylcholinesterase, reduces oxidative stress and neuronal inflammation, and activates neurotrophic pathways such as TrkB/CREB/BDNF.
- Potential as a neuroprotective nutraceutical in early stages of cognitive decline.